Citicoline in acute ischemic stroke: A randomized controlled trial

• Published in: PloS one 2022-05, Vol.17 (5), p.e0269224-e0269224
• Main Authors: Agarwal, Ayush, Vishnu, Venugopalan Y, Sharma, Jyoti, Bhatia, Rohit, Garg, Ajay, Dwivedi, Sadanand, Upadhyay, Ashish, Goyal, Vinay, Singh, Mamta Bhushan, Gupta, Anu, Rajan, Roopa, Srivastava, M V Padma
• Format: Article
• Language: English
• Subjects: Brain Ischemia - complications; Brain Ischemia - drug therapy; Care and treatment; Citicoline; Clinical trials; Cytidine diphosphate choline; Cytidine Diphosphate Choline - therapeutic use; Dementia; Double-Blind Method; Ethical standards; Health aspects; Humans; Intravenous administration; Ischemia; Ischemia - drug therapy; Ischemic Stroke; Medical science; Medicine and Health Sciences; Mortality; Neuroprotection; Patients; People and Places; Placebos; Research and Analysis Methods; Statistical analysis; Stroke; Stroke (Disease); Stroke - complications; Stroke - drug therapy; Stroke volume; Therapy
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0269224

Two pharmacological possibilities exist for an acute ischemic stroke (AIS): recanalization of the occluded artery and neuroprotection from ischaemic injury, the latter's efficacy being debatable. We sought to determine whether administration of Citicoline immediately after recanalization therapy for AIS would improve clinical and radiological outcome at three months compared to standard treatment alone. CAISR was a single centre, randomized, placebo-controlled, parallel-group trial with blinded endpoint assessment. It was approved by the All India Institute of Medical Sciences Institutional ethics committee and registered at the Clinical Trial Registry of India (CTRI/2018/011900). We recruited participants with AIS undergoing recanalization therapy and randomly assigned them to receive either Citicoline or placebo in 1:1 ratio. Citicoline arm patients received Citicoline 1gm BD intravenously for three days, followed by oral citicoline 1gm BD for 39 days. Placebo arm patients received 100ml intravenous normal saline for three days, followed by multivitamin tablet BD for 39 days. All patients received standard of care. Blinded assessors did the follow-up assessment at six weeks (MRI Brain-stroke volume) and three months (NIHSS 0-2, mRS 0-2 and Barthel index> = 95). The infarct volume decreased from week 1 to week 6 by 2.6 cm3 on placebo versus 4.2 cm3 on Citicoline (p-0.483). The OR for achieving NIHSS 0-2, mRS 0-2 and Barthel index> = 95 with Citicoline was found to be 0.96(95%CI 0.39-2.40), 0.92(95%CI 0.40-2.05) and 0.87(95%CI 0.22-2.98) respectively. CAISR was the first to evaluate the role of Citicoline, when used immediately after recanalization therapy, when the penumbral tissue is the most susceptible either to be protected from injury or become ischemic. We did not find any significant difference between the Citicoline or placebo arms with respect to either our primary or secondary outcomes.